Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
Top Cited Papers
- 14 September 2011
- journal article
- research article
- Published by Elsevier
- Vol. 162 (4) , 597-605
- https://doi.org/10.1016/j.ahj.2011.06.012
Abstract
No abstract availableKeywords
This publication has 63 references indexed in Scilit:
- C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysisThe Lancet, 2009
- Inflammation in AtherosclerosisJournal of the American College of Cardiology, 2009
- Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)Journal of Thrombosis and Haemostasis, 2009
- C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart StudyCirculation: Cardiovascular Quality and Outcomes, 2008
- C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk: Moving an Inflammatory Hypothesis Toward ConsensusPublished by Elsevier ,2007
- The Effect of Including C-Reactive Protein in Cardiovascular Risk Prediction Models for WomenAnnals of Internal Medicine, 2006
- The immune response in atherosclerosis: a double-edged swordNature Reviews Immunology, 2006
- Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular EventsNew England Journal of Medicine, 2002
- C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in WomenNew England Journal of Medicine, 2000
- Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy MenNew England Journal of Medicine, 1997